

**REMARKS**

Upon entry of the Amendment, which is respectfully requested, claims 1-5 will be all the claims pending in the present application.

Claims 1-5 are amended to clearly recited the claimed subject matter of the present application. Support for the amendment can be found at least at page 3, paragraph 3.

In response to the Restriction Requirement, Applicants elect **Group B**, claims 1-5, drawn to a method of using angelicin or a structural analogue thereof for the treatment of beta-thalassaemia, for examination. This election is made without traverse.

In response to the Election of Species Requirement, Applicants elect angelicin as (i) a specific compound from "angelicin or structural analogue thereof". Claims 1-5 read on the elected species. This election is made without traverse.

Applicants submit that if any of the elected claims is found to be allowable, claims dependent therefrom should similarly be considered allowable in the same application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

PRELIMINARY AMENDMENT  
U.S. Application No.: 10/522,737

Attorney Docket No.: Q86049

Entry and consideration of this Amendment are respectfully requested.


Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

  
Susan J. Mack  
Registration No. 30,951

Date: May 20, 2008